35 Folgen

  1. Dex and the Cytokine City: Managing CRS with Bispecifics

    Vom: 7.4.2025
  2. LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML

    Vom: 11.3.2025
  3. Episode 32: Navigating a BlinatumoMAD World

    Vom: 21.1.2025
  4. The Aquila Study: Blowing Hot Air or a Soaring Success for Smoldering Multiple Myeloma

    Vom: 15.1.2025
  5. Pour Decisions, or ASH-olutely Fabulous? Reviewing 2024 ASH Lymphoma Updates

    Vom: 24.12.2024
  6. A Bunch of ASHholes Discuss Myeloma Abstracts

    Vom: 16.11.2024
  7. Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

    Vom: 8.11.2024
  8. Episode 27: Mantle Cell Masterclass with Tycel Phillips

    Vom: 10.10.2024
  9. Houston, we don't have a problem... with APOLLO

    Vom: 28.8.2024
  10. From Ancient Remedies to Modern Miracles: The Evolution of APL Treatment

    Vom: 13.6.2024
  11. Episode 24: Myeloma Madness with the Myeloma Man

    Vom: 17.4.2024
  12. Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion

    Vom: 25.1.2024
  13. LymphOMG: Pouring Over Lymphoma Abstracts from ASH

    Vom: 29.12.2023
  14. AMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven Alchemy

    Vom: 19.12.2023
  15. ASH Pregaming - Myeloma Madness with Manni and Papa Heme

    Vom: 1.12.2023
  16. AML Maintenance Part 2: a metaMORPHOsis?

    Vom: 8.11.2023
  17. AML Maintenance Part 1: Set Your QUAZARs to Stun

    Vom: 25.10.2023
  18. Episode 17: The Hemophilia Eras Tour

    Vom: 23.8.2023
  19. Common Sense Oncology: Outcomes That Matter

    Vom: 1.8.2023
  20. All too well: the reality of leukemia treatment

    Vom: 8.6.2023

1 / 2

Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.

Visit the podcast's native language site